In Zucker diabetic fatty rats, subclinical diabetic neuropathy increases in vivo lidocaine block duration but not in vitro neurotoxicity

Regional Anesthesia and Pain Medicine

Volumn 37, Issue 6, 2012, Pages 601-606

  Lirk, Philipp ^a,b   Flatz, Magdalena ^b   Haller, Ingrid ^a   Hausott, Barbara ^c   Blumenthal, Stephan ^d   Stevens, Markus F ^a   Suzuki, Suzuko ^e   Klimaschewski, Lars ^c   Gerner, Peter ^e,f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d TRIEMLI HOSPITAL   (Switzerland)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GLUCOSE; LIDOCAINE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL SURVIVAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; ENZYME INHIBITION; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LOCAL ANESTHESIA; MALE; MOTOR PERFORMANCE; NERVE BLOCK; NERVE CELL CULTURE; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SENSORY NERVE CELL; SPINAL GANGLION; ZUCKER DIABETIC FATTY RAT;

ANESTHETICS, LOCAL; ANIMALS; BEHAVIOR, ANIMAL; CELL COUNT; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; IMIDAZOLES; L-LACTATE DEHYDROGENASE; LIDOCAINE; MALE; NERVE BLOCK; NEURONS; NOCICEPTION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; RATS, ZUCKER; SCIATIC NERVE; TIME FACTORS;

EID: 84868272788     PISSN: 10987339     EISSN: 15328651     Source Type: Journal    
DOI: 10.1097/AAP.0b013e3182664afb     Document Type: Article

References (33)

1. Auroy Y, Benhamou D, Bouaziz H, et al. Peripheral nerve block: yesterday's facts and tomorrow's challenges. Ann Fr Anesth Reanim. 2006;25:82-83.
2. Hebl JR, Kopp SL, Schroeder DR, Horlocker TT. Neurologic complications after neuraxial anesthesia or analgesia in patients with preexisting peripheral sensorimotor neuropathy or diabetic polyneuropathy. Anesth Analg. 2006;103:1294-1299.
3. Lirk P, Birmingham B, Hogan Q. Regional anesthesia in patients with preexisting neuropathy. Int Anesthesiol Clin. 2011;49:144-165.
4. Blumenthal S, Borgeat A, Maurer K, et al. Preexisting subclinical neuropathy as a risk factor for nerve injury after continuous ropivacaine administration through a femoral nerve catheter. Anesthesiology. 2006;105:1053-1056.
5. Said G. Diabetic neuropathyVa review. Nat Clin Pract Neurol. 2007;3:331-340.
6. Kalichman MW, Calcutt NA. Local anestheticYinduced conduction block and nerve fiber injury in streptozotocin-diabetic rats. Anesthesiology. 1992;77:941-947.
7. Kroin JS, Buvanendran A, Williams DK, et al. Local anesthetic sciatic nerve block and nerve fiber damage in diabetic rats. Reg Anesth Pain Med. 2010;35:343-350.
8. Kroin JS, Buvanendran A, Tuman KJ, Kerns JM. Safety of local anesthetics administered intrathecally in diabetic rats. Pain Med. 2012;13:802-807.
9. Brull R, McCartney CJ, Chan VW, El-Beheiry H. Neurological complications after regional anesthesia: contemporary estimates of risk. Anesth Analg. 2007;104:965-974.
10. Hebl JR, Horlocker TT, Pritchard DJ. Diffuse brachial plexopathy after interscalene blockade in a patient receiving cisplatin chemotherapy: the pharmacologic double crush syndrome. Anesth Analg. 2001;92:249-251.
11. Haller I, Hausott B, Tomaselli B, et al. Neurotoxicity of lidocaine involves specific activation of the p38 mitogen-activated protein kinase, but not extracellular signalYregulated or c-jun N-terminal kinases, and is mediated by arachidonic acid metabolites. Anesthesiology. 2006;105:1024-1033.
12. Price SA, Agthong S, Middlemas AB, Tomlinson DR. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes. 2004;53:1851-1856.
13. Echevarria M, Hachero A, Martinez A, et al. Spinal anaesthesia with 0.5% isobaric bupivacaine in patients with diabetes mellitus: the influence of CSF composition on sensory and motor block. Eur J Anaesthesiol. 2008;25:1014-1019.
14. Lelkes E, Unsworth BR, Lelkes PI. Reactive oxygen species, apoptosis and altered NGF-induced signaling in PC12 pheochromocytoma cells cultured in elevated glucose: an in vitro cellular model for diabetic neuropathy. Neurotox Res. 2001;3:189-203.
15. Lirk P, Haller I, Colvin H, et al. In vitro, inhibition of stress-activated protein kinase pathways protects against bupivacaine- and ropivacaine-induced neurotoxicity. Anesth Analg. 2008;106:1456-1464.
16. Lirk P, Haller I, Colvin HP, et al. In vitro, lidocaine-induced axonal injury is prevented by peripheral inhibition of the p38 mitogen-activated protein kinase, but not by inhibiting caspase activity. Anesth Analg. 2007;105:1657-1664.
17. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab. 2005;7:307-317.
18. Etgen GJ, Oldham BA. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism. 2000;49:684-688.
19. Oltman CL, Coppey LJ, Gellett JS, Davidson EP, Lund DD, Yorek MA. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am J Physiol Endocrinol Metab. 2005;289:E113YE122.
20. Brussee V, Guo G, Dong Y, et al. Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model. Diabetes. 2008;57:1664-1673.
21. Lirk P, Haller I, Myers RR, et al. Mitigation of direct neurotoxic effects of lidocaine and amitriptyline by inhibition of p38 mitogen-activated protein kinase in vitro and in vivo. Anesthesiology. 2006;104:1266-1273.
22. Gerner P, Haderer AE, Mujtaba M, et al. Assessment of differential blockade by amitriptyline and its N-methyl derivative in different species by different routes. Anesthesiology. 2003;98:1484-1490.
23. Thalhammer JG, Vladimirova M, Bershadsky B, Strichartz GR. Neurologic evaluation of the rat during sciatic nerve block with lidocaine. Anesthesiology. 1995;82:1013-1025.
24. Gerner P, Binshtok AM, Wang CF, et al. Capsaicin combined with local anesthetics preferentially prolongs sensory/nociceptive block in rat sciatic nerve. Anesthesiology. 2008;109:872-878.
25. Zochodne DW, Cheng C, Sun H. Diabetes increases sciatic nerve susceptibility to endothelin-induced ischemia. Diabetes. 1996;45:627-632.
26. Zochodne DW, Cheng C. Diabetic peripheral nerves are susceptible to multifocal ischemic damage from endothelin. Brain Res. 1999;838:11-17.
27. Williams BA, Murinson BB, Grable BR, Orebaugh SL. Future considerations for pharmacologic adjuvants in single-injection peripheral nerve blocks for patients with diabetes mellitus. Reg Anesth Pain Med. 2009;34:445-457.
28. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807-869.
29. Obata K, Yamanaka H, Kobayashi K, et al. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci. 2004;24:10211-10222.
30. Park JY, Kim EJ, Kwon KJ, et al. Neuroprotection by fructose-1,6- bisphosphate involves ROS alterations via p38 MAPK/ERK. Brain Res. 2004;1026:295-301.
31. Horstmann S, Kahle PJ, Borasio GD. Inhibitors of p38 mitogen-activated protein kinase promote neuronal survival in vitro. J Neurosci Res. 1998;52:483-490.
32. Haller I, Lirk P, Keller C, Wang GK, Gerner P, Klimaschewski L. Differential neurotoxicity of tricyclic antidepressants and novel derivatives in vitro in a dorsal root ganglion cell culture model. Eur J Anaesthesiol. 2007;24:702-708.
33. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev. 1992;44:103-150.